A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab, PMID: 34447766
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark Special Reporting on:• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With Vedolizumab PLUS Meeting Abstract Summaries With Expert Commentary by: Edward V. Loftus Jr, MD Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota, PMID: 31632213
Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease, PMID: 30571147
Anti-interleukin-23 agents for the treatment of ulcerative colitis, PMID: 31760827
Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks, PMID: 33098883
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease, PMID: 33105016
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis, PMID: 32950748
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study, PMID: 30734266
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis, PMID: 31493397
Emerging systemic drugs in the treatment of plaque psoriasis, PMID: 32192366
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More, PMID: 32570252
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?, PMID: 31327402
IL-23 inhibitors for moderate-to-severe psoriasis, PMID: 30215632
Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment, PMID: 29796240
Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review, PMID: 32530083
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease, PMID: 30056776
Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules, PMID: 34239295
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis, PMID: 31447673
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review, PMID: 32427307
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis, PMID: 33871055
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges, PMID: 34079536
Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis, PMID: 32166932
Impact of Mirikizumab Treatment on Fatigue in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study., PMID:40491246
Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations., PMID:40465057
Guselkumab (Tremfya) - an IL-23 antagonist for Crohn's disease., PMID:40459404
IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody., PMID:40455166
First Documented Case of Successful Dual Therapy With Upadacitinib and Mirikizumab for Multi-Refractory Ulcerative Proctitis., PMID:40411442
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?, PMID:40394835
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective., PMID:40351121
Mirikizumab (Omvoh) - an IL-23 antagonist for Crohn's disease., PMID:40324965
Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse. Authors' Reply., PMID:40321062
Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse., PMID:40321049
Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials., PMID:40301737
Efficacy and safety of mirikizumab in the treatment of inflammatory bowel disease: A meta-analysis., PMID:40295305
New Interleukin-23 Antagonists' Use in Crohn's Disease., PMID:40283885
Efficacy and Safety of Mirikizumab in the Treatment of Moderately to Severely Active Ulcerative Colitis Regardless of Baseline Modified Mayo Score: Results From the Phase 3 LUCENT Trials., PMID:40260308
Mirikizumab for Ulcerative Colitis: A Game-Changer or Just Another Incremental Advance?, PMID:40237908
Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study., PMID:40205711
Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series., PMID:40198002
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials., PMID:40117091
Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies., PMID:40095460
IL23p19 therapies for moderately-to-severely active ulcerative colitis., PMID:40082083
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study., PMID:40079470
Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis., PMID:40071779
Combining mechanistic modeling with machine learning as a strategy to predict inflammatory bowel disease clinical scores., PMID:40070575
Guselkumab (Tremfya) for ulcerative colitis., PMID:40053377
Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center., PMID:40048134
Drug Development in Inflammatory Bowel Diseases: What Is Next?, PMID:40006003
Epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years., PMID:39994836
The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn's disease., PMID:39954670
Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials., PMID:39954188
Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease-From Bench to Bedside., PMID:39941671
Mirikizumab for Crohn's Disease: Small Step Forward or Giant Leap Ahead?, PMID:39914777
Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With Up to 3 Years of Treatment., PMID:39896691
Exit Interviews Exploring Patients' Experience of Change in Crohn's Disease Symptoms During the Mirikizumab Phase 3 Clinical Trial In Adult Patients With Moderately-to-Severely Crohn's Disease., PMID:39834356
Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis., PMID:39693227
The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn's Disease., PMID:39692838
Targeting mucosal healing in Crohn's disease: efficacy of novel pathways and therapeutic targets., PMID:39611536
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study., PMID:39581202
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis., PMID:39572132
Mirikizumab for Chronic Plaque Psoriasis: A Systematic Review and Meta-Analysis., PMID:39570737
Risankizumab (Skyrizi) for ulcerative colitis., PMID:39509158
Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey., PMID:39473630
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study., PMID:39448057
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis., PMID:39425738
Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: a Systematic Review and Network Meta-analysis., PMID:39404996
Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis., PMID:39367678
An evaluation of mirikizumab for the treatment of ulcerative colitis., PMID:39360778
Mirikizumab for the treatment of chronic antibiotic-refractory pouchitis., PMID:39321965
Efficacy and safety of mirikizumab compared with currently approved biologic drugs for the treatment of ulcerative colitis: A systematic review and network meta-analysis., PMID:39320112
Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases., PMID:39308999
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review., PMID:39303214
For research use only. Not for human or drug use.
